• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Shineco Inc.

    10/25/24 2:45:17 PM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $SISI alert in real time by email
    SC 13G/A 1 SISI_SC13G.txt SISI 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Shineco, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 824567408 (CUSIP Number) John Fife, 303 E Wacker Dr, Suite 1040 Chicago, IL 60601 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) October 25, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ? Rule 13d-1(b) X Rule 13d-1(c) ? Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).? CUSIP No. 824567408 13G Page 2 of 8 Pages 1. NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Streeterville Capital LLC 85-2954598 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) ? (b) ? 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Utah NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 3,275,966 6. SHARED VOTING POWER 0 7. SOLE DISPOSITIVE POWER 3,275,966 8. SHARED DISPOSITIVE POWER 0 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,275,966 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) ? 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 9.99% (*) 12. TYPE OF REPORTING PERSON (see instructions) OO FOOTNOTES * Reporting Person Streeterville Capital LLC (?Streeterville?) has rights under a Convertible Promissory Note to own an aggregate number of shares of the Issuer?s common shares which, except for a contractual cap on the amount of outstanding shares that Streeterville may own, would exceed such cap. Streeterville's current ownership cap is 9.99%. Thus, the number of shares of the Issuer's common shares beneficially owned by Streeterville as of the date of this filing was 3,275,966 shares, which is 9.99% of the 32,792,456 shares outstanding on September 16, 2024 (as reported in the Issuer's Schedule 14A filed on October 4, 2024). ? CUSIP No. 824567408 13G Page 3 of 8 Pages 1. NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Streeterville Management LLC 85-3223919 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) ? (b) ? 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 3,275,966 6. SHARED VOTING POWER 0 7. SOLE DISPOSITIVE POWER 3,275,966 8. SHARED DISPOSITIVE POWER 0 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,275,966 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) ? 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 9.99% (*) 12. TYPE OF REPORTING PERSON (see instructions) OO FOOTNOTES * Reporting Person Streeterville Management, LLC is the Manager of reporting person Streeterville. Streeterville has rights under a Convertible Promissory Note to own an aggregate number of shares of the Issuer?s common shares which, except for a contractual cap on the amount of outstanding shares that Streeterville may own, would exceed such cap. Streeterville's current ownership cap is 9.99%. Thus, the number of shares of the Issuer's common shares beneficially owned by Streeterville as of the date of this filing was 3,275,966 shares, which is 9.99% of the 32,792,456 shares outstanding on September 16, 2024 (as reported in the Issuer's Schedule 14A filed on October 4, 2024). ? CUSIP No. 824567408 13G Page 4 of 8 Pages 1. NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) John M. Fife 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) ? (b) ? 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION United States of America NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 3,275,966 6. SHARED VOTING POWER 0 7. SOLE DISPOSITIVE POWER 3,275,966 8. SHARED DISPOSITIVE POWER 0 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,275,966 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) ? 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 9.99% (*) 12. TYPE OF REPORTING PERSON (see instructions) IN FOOTNOTES * John M. Fife is the sole member of Streeterville Management LLC, which is the Manager of Reporting Person Streeterville. Streeterville has rights under a Convertible Promissory Note to own an aggregate number of shares of the Issuer?s common shares which, except for a contractual cap on the amount of outstanding shares that Streeterville may own, would exceed such cap. Streeterville's current ownership cap is 9.99%. Thus, the number of shares of the Issuer's common shares beneficially owned by Streeterville as of the date of this filing was 3,275,966 shares, which is 9.99% of the 32,792,456 shares outstanding on September 16, 2024 (as reported in the Issuer's Schedule 14A filed on October 4, 2024). ? CUSIP No. 824567408 13G Page 5 of 8 Pages Item 1. (a) Name of Issuer Shineco, Inc. (b) Address of Issuer?s Principal Executive Offices Room 1707, Block D, Modern City SOHO, No. 88, Jianguo Road, Chaoyang District Beijing, PRC Item 2. (a) Name of Person Filing This report is filed by Streeterville Capital LLC, Streeterville Management LLC, and John M. Fife with respect to the shares of Common Stock, $0.001 par value per share, of the Issuer that are directly beneficially owned by Streeterville Capital LLC and indirectly beneficially owned by the other reporting and filing persons. (b) Address of the Principal Office or, if none, residence 303 East Wacker Drive, Suite 1040, Chicago, IL 60601 (c) Citizenship Streeterville Capital LLC is a Utah limited liability company. Streeterville Management LLC is a Utah limited liability company. John M. Fife is a United States citizen. (d) Title of Class of Securities Common Stock, $0.001 par value per share (e) CUSIP Number 824567408 Item 3. If this statement is filed pursuant to ??240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) ? Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). (b) ? Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) ? Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (d) ? Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). (e) ? An investment adviser in accordance with ?240.13d-1(b)(1)(ii)(E); (f) ? An employee benefit plan or endowment fund in accordance with ?240.13d- 1(b)(1)(ii)(F); (g) ? A parent holding company or control person in accordance with ?240.13d- 1(b)(1)(ii)(G); (h) ? A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) ? A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) ? Group, in accordance with ?240.13d-1(b)(1)(ii)(J). Item 4. Ownership. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: 3,275,966 (b) Percent of class: 9.99% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 3,275,966 (ii) Shared power to vote or to direct the vote: 0 (iii) Sole power to dispose or to direct the disposition of: 3,275,966 (iv) Shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ? . N/A Item 6. Ownership of More than Five Percent on Behalf of Another Person. N/A Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. N/A Item 8. Identification and Classification of Members of the Group. N/A Item 9. Notice of Dissolution of Group. N/A Item 10. Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. CUSIP No. 824567408 13G Page 8 of 8 Pages After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. 10/25/2024 Date Streeterville Capital LLC /s/ John Fife Signature John Fife/President Name/Title Streeterville Management LLC /s/ John Fife Signature John Fife/President Name/Title John M. Fife /s/ John Fife Signature John Fife Name/Title
    Get the next $SISI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SISI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SISI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Shineco Announces Acquisition of Singapore Evolutionary Stem Cell Company

      Expanding the Frontiers of Regenerative Medicine BEIJING, April 23, 2025 (GLOBE NEWSWIRE) -- Shineco, Inc. ((", Shineco", or the ", Company", , NASDAQ:SISI), a provider of innovative diagnostic medical products and related medical devices, announced today that on April 22, 2025, its subsidiary, Shineco Life Sciences Group Hong Kong Limited ("Shineco Life Sciences"), entered into a Share Purchase Agreement (the "SPA") with Dr. Lim Kah Meng (the "Seller") to acquire 51% of the equity interest in InfiniClone Limited, a company incorporated under the laws of Hong Kong that has been wholly owned held by Dr. Lim ("InfiniClone"). InfiniClone is a biotechnology company focusing on the field of re

      4/23/25 9:00:00 AM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Shineco Announces Acquisition of Medical Device Company

      The Acquisition is Expected to Create Immediate Synergies with the Company's Existing Medical Device Business  BEIJING, March 25, 2025 (GLOBE NEWSWIRE) -- Shineco, Inc. (("Shineco" or the "Company", NASDAQ:SISI), a provider of innovative diagnostic medical products and related medical devices, announced today that on March 20, 2025, Shineco Life Science Group Hong Kong Co., Limited ("Shineco Life Science"), a subsidiary of the Company, entered into a Stock Purchase Agreement ("SPA") with Yi Yang (the "Seller"), for 75% of an equity interest in FuWang (HK) International Company Limited ("FuWang Company"). The Seller is the current and only shareholder of FuWang Company, which specializes i

      3/25/25 9:00:00 AM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Shineco Announces Reverse Split to Regain NASDAQ Compliance

      BEIJING, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Shineco Inc. (("Shineco" or the "Company", NASDAQ:SISI), a producer of innovative diagnostic medical products and related medical devices, announced today that effective at 12:01 a.m., EDT, on November 12, 2024, the Company will effect a one-for-twenty four (1-for-24) reverse stock split of its outstanding common stock (the "Reverse Stock Split"). The Reverse Stock Split is primarily intended to bring the Company into compliance with the minimum average closing share price requirement for maintaining its listing on the Nasdaq Capital Market. The Company's common stock will continue to trade under the symbol "SISI". Upon the effectiveness of the R

      11/12/24 9:00:00 AM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care

    $SISI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Shineco Inc.

      SC 13G/A - SHINECO, INC. (0001300734) (Subject)

      10/25/24 2:45:17 PM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D filed by Shineco Inc.

      SC 13D - SHINECO, INC. (0001300734) (Subject)

      7/12/24 5:28:03 PM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Shineco Inc.

      SC 13G - SHINECO, INC. (0001300734) (Subject)

      8/29/23 1:26:38 PM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care

    $SISI
    Leadership Updates

    Live Leadership Updates

    See more
    • Future FinTech Announces the Appointment of Hu Li as the New CEO

      NEW YORK, Aug. 9, 2024 /PRNewswire/ -- Future Fintech Group Inc. (NASDAQ: FTFT), (hereinafter referred to as "Future FinTech", "FTFT" or the "Company"), a comprehensive financial and digital technology service provider, today announced that its Board of Directors (the "Board") approved the appointment of Mr. Hu Li as Chief Executive Officer ("CEO"), President and a member of the Board of the Company, effective August 5, 2024. Mr. Li will be fully responsible for the operation and management of the Company, helping it to expand internationally, manage its investment and financi

      8/9/24 9:00:00 AM ET
      $FTFT
      $SISI
      Business Services
      Consumer Discretionary
      Medicinal Chemicals and Botanical Products
      Health Care
    • Shineco Announces the Appointment of Two New Executive Officers

      BEIJING, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Shineco, Inc. (("Shineco" or the "Company", NASDAQ:SISI), a provider of technologically advanced healthcare products and services, announced today that its Board of Directors has appointed Ms. Xiaohui Wang and Mr. Chi Keung Yan as executive officers of the Company in key leadership roles. Effective November 13, 2023, Shineco's Board of Directors appointed Ms. Xiaohui Wang as Executive President of the Company. From March 2000 to November 2013, Ms. Wang was the founder and Chairperson of Chongqing Wintus (New Star) Enterprises Group, where she was responsible for its corporate planning, supervision of the group's business in the Chongqing region,

      11/17/23 9:00:00 AM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Shineco, Inc. Appoints Professor Qiyin Sun as Chief Medical Consultant

      BEIJING, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Shineco, Inc. (("Shineco" or the "Company", NASDAQ:SISI), a producer and distributor of Chinese herbal medicines, organic agricultural and other biotech products, announced that the Company has appointed Professor Qiyin Sun as the Chief Medical Consultant. Professor Sun will lead the research and innovation of the Company's tumor treatment and provide technical consultation in early tumor screening and tumor radiotherapy to support the commercialization of digital tumor diagnosis and treatment. Prior to serving as the chief medical consultant at Shineco, Professor Sun was a director at Beijing Nuclear Medicine Equipment Engineering Technology R

      2/1/22 9:00:00 AM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care

    $SISI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Huang Shanchun claimed ownership of 5,041,667 shares (SEC Form 3)

      3 - SHINECO, INC. (0001300734) (Issuer)

      4/24/25 4:05:15 PM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 3 filed by new insider Yan Chi Keung

      3 - SHINECO, INC. (0001300734) (Issuer)

      12/7/23 4:10:17 PM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 3 filed by new insider Wang Xiaohui

      3 - SHINECO, INC. (0001300734) (Issuer)

      12/7/23 4:10:16 PM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care

    $SISI
    SEC Filings

    See more
    • Shineco Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - SHINECO, INC. (0001300734) (Filer)

      4/23/25 9:00:37 AM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Shineco Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - SHINECO, INC. (0001300734) (Filer)

      3/20/25 2:30:26 PM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form EFFECT filed by Shineco Inc.

      EFFECT - SHINECO, INC. (0001300734) (Filer)

      3/20/25 12:15:03 AM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care